跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Medac Gesellschaft für klinische Spezialpräparate m.b.H.

首页临床试验发起方与机构Medac Gesellschaft für klinische Spezialpräparate m.b.H.

Medac Gesellschaft für klinische Spezialpräparate m.b.H.

ACTIVE

Theaterstr. 6, Wedel, Schleswig-Holstein, 德国Private

别名:

medac gmbh

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

42

18 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

20

47.6%

3 期

9

21.4%

2 期

8

19.1%

早期 1 期

1

2.4%

试验状态分布

进行中（未招募）

18

42.9%

已完成

19

45.2%

招募中

3

7.1%

终止

2

4.8%

相关临床试验

该机构主办的试验（42）

-An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101

100 名受试者

Safety, efficacy, and PK of treosulfan in adult Japanese participants with haematological malignancies

36 名受试者

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Feb 2024277 名受试者

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Feb 202420 名受试者

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

进行中（未招募）

Nov 202349 名受试者

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Aug 2021210 名受试者

An assessor-blinded, subject-blinded, double-dummy, active-controlled, randomised trial to compare the safety and efficacy of subcutaneous methotrexate (MJK101) with oral methotrexate in methotrexate-naive subjects with active rheumatoid arthritis followed by an open-label, single-arm extension to assess the long-term safety of MJK101

Aug 2019103 名受试者

PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia

进行中（未招募）

Apr 201940 名受试者

药物批准

暂无批准数据

资讯

FDA Approves GRAFAPEX (Treosulfan) for Injection in AlloHSCT Conditioning Regimen

- The FDA has approved GRAFAPEX (treosulfan) in combination with fludarabine for allogeneic hematopoietic stem cell transplantation (alloHSCT) conditioning. - GRAFAPEX is indicated for adult and pediatric patients (1 year+) with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). - Clinical trials showed GRAFAPEX, combined with fludarabine, improved overall survival compared to busulfan-based regimens in transplant settings. - Medexus Pharmaceuticals plans to launch GRAFAPEX in the first half of 2025, projecting potential annual revenue exceeding $100 million within five years.

本页目录

概览
相关临床试验42
药物批准
资讯1

返回机构列表